Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 18/20 | 0.81 |
| ▸ | SLC6A4 known ✓ | P31645 | 17/20 | 0.81 |
| ▸ | SLC6A2 known ✓ | P23975 | 10/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.81 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.81 |
| ▸ | HTR2B | P41595 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL4880870 | 0.99 | SLC6A3 (0.82) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL3706698 | 0.95 | SLC6A3 (0.85) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL4855874 | 0.92 | SLC6A3 (0.79) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL6431587 | 0.91 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL2916993 | 0.91 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL3855473 | 0.90 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL4594859 | 0.90 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL42301 | 0.90 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL4051966 | 0.90 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL2672138 | 0.90 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081826-A1 | SYSTEM FOR EFFECTING WEIGHT LOSS | ABBOTT LABORATORIES | 2008-04-03 | — | — | US | claimed |
| CN-100342851-C | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI PHARM IND CO LTD (KR) | 2007-10-17 | — | — | CN | claimed |
| CN-1688297-A | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI PHARM IND CO LTD (KR) | 2005-10-26 | — | — | CN | claimed |
| EP-1545484-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE SIBUTRAMINE METHANESULFONATE HEMIHYDRATE | Hanmi Pharm. Co., Ltd. (KR) | 2005-06-29 | — | — | EP | claimed |
| US-6900245-B2 | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI PHARM. CO., LTD. (KR) | 2005-05-31 | — | — | US | claimed |
| WO-2004030663-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE SIBUTRAMINE METHANESULFONATE HEMIHYDRATE | HANMI PHARM. CO., LTD. (KR) | 2004-04-15 | — | — | WO | claimed |
| US-20040068018-A1 | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI HOLDINGS CO., LTD. (KR) | 2004-04-08 | — | — | US | claimed |
| US-9931346-B2 | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-04-03 | — | — | US | disclosed |
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-27 | — | — | US | disclosed |
| EP-3082782-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | disclosed |
| CN-105873578-A | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and sigma receptor ligands combinations | 埃斯蒂维实验室股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| WO-2015091508-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-20080194695-A1 | Pharmaceutical Composition Containing Sibutramine Free Base and Manufacturing Method Thereof | CTCBIO, INC. (KP) | 2008-08-14 | — | — | US | disclosed |
| US-6900245-B2 | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI PHARM. CO., LTD. (KR) | 2005-05-31 | — | — | US | disclosed |
| US-6900245-B2 | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI PHARM. CO., LTD. (KR) | 2005-05-31 | — | — | US | disclosed |
| WO-2004030663-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE SIBUTRAMINE METHANESULFONATE HEMIHYDRATE | HANMI PHARM. CO., LTD. (KR) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004030663-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE SIBUTRAMINE METHANESULFONATE HEMIHYDRATE | HANMI PHARM. CO., LTD. (KR) | 2004-04-15 | — | — | WO | disclosed |
| US-20040068018-A1 | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI HOLDINGS CO., LTD. (KR) | 2004-04-08 | — | — | US | disclosed |
| US-20040068018-A1 | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI HOLDINGS CO., LTD. (KR) | 2004-04-08 | — | — | US | disclosed |
| US-20040068018-A1 | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HANMI HOLDINGS CO., LTD. (KR) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, SLC6A2 | SLC6A3 29/4885SLC6A4 6/4885SLC6A2 3/4885 |
| US-20040068018-A1 | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | HTR5A, CMA1, HTR6 | SLC6A3 45/4885SLC6A4 39/4885SLC6A2 55/4885 |
| US-20080081826-A1 | SYSTEM FOR EFFECTING WEIGHT LOSS | GIPR, MGLL, GLP1R | SLC6A3 696/4885SLC6A4 746/4885SLC6A2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.